Perhaps I could speak a bit about an international initiative that we have embarked on with five other MS societies worldwide. We recognized that there was a need to address the issue of progressive MS, which is the most debilitating form of MS. At the time, there were no drugs available. Five of the MS societies came together globally, and we formed an alliance. We each contribute at least one million euros. We now have a 30-million-euro initiative.
What's interesting here is that we also work with global industry players. They also are contributing at a global level. When we talk about open access, our aim is to make sure that the data being generated in this alliance globally is also available in open access. For instance, there's a researcher out of the MNI who is being funded. Interestingly, he's analyzing data from clinical trials from industry. They have let go of their industry data and have provided it to him to ensure that he can do the proper analysis. I think when we talk about manners of partnership and collaboration, that's a great example of how we're doing it at an international scale, using the resources within the Canadian community as well as partnering with industry. I know we've heard a lot of negativity around industry, but I think there are ways to partner to ensure that we reach our mandates of better access to treatments and developing new treatments.